Slide 1: Baseline Characteristics of Patients Who Did or Did Not Maintain 12- & 16-Week Aflibercept 8 mg Dosing Intervals
Baseline Characteristics of Patients Who Did or Did Not Maintain 12- & 16- Week Aflibercept 8 mg Dosing Intervals in the Phase 2/3 PHOTON Trial Sobha Sivaprasad,1 on behalf of the PHOTON study investigators 1Moorfields Eye Hospital, London, UK Presented at the 23rd European Society of Retina Special
Slide 2: Disclosures
Disclosures DME • Dr Sivaprasad receives funding/fees from Allergan, Apellis, Bayer, Biogen, Boehringer Ingelheim, EyeBiotech, Novartis, Optos, and Roche. • This study was sponsored by Regeneron Pharmaceuticals, Inc. (Tarrytown, NY) and co-funded by Bayer AG (Leverkusen, Germany). The sponsors parti
Slide 3: PHOTON: Study Design and Dosing Schedule
PHOTON: Study Design and Dosing Schedule DME
Slide 4: PHOTON: 48-Week BCVA Primary Endpoint Met in Both 8 mg Groups
PHOTON: 48-Week BCVA Primary Endpoint Met in Both 8 mg Groups DME BCVA Change From Baselinea
Slide 5: Proportion of 8 mg Patients Maintaining Q12- and Q16-Week Intervals Through Week 48
Proportion of 8 mg Patients Maintaining Q12- and Q16-Week Intervals Through Week 48 DME 93% of 8 mg patients maintained dosing intervals ≥12 weeks
Slide 6: Baseline Demographics by Dosing Interval
Baseline Demographics by Dosing Interval DME
Slide 7: Baseline Demographics by Dosing Interval
Baseline Demographics by Dosing Interval DME
Slide 8: Baseline Ocular Characteristics by Dosing Interval
Baseline Ocular Characteristics by Dosing Interval DME
Slide 9: Absolute BCVA and CRT at Baseline and Week 48 by Dosing Interval
Absolute BCVA and CRT at Baseline and Week 48 by Dosing Interval DME
Slide 10: Conclusions
Conclusions DME • Aflibercept 8q12 and 8q16 demonstrated non-inferior BCVA gains compared to aflibercept 2q8 at Week 48, with a large majority of patients maintaining their randomized 12- or 16-week dosing intervals – Dosing intervals were shortened in approximately 10% of patients • Lower BCVA and